Development and Validation of a Prognostic Score Predicting Recurrence in Resected Combined Hepatocellular Cholangiocarcinoma

Meng-Xin Tian,Liu-Ping Luo,Wei-Ren Liu,Wei Deng,Jia-Cheng Yin,Lei Jin,Xi-Fei Jiang,Yu-Fu Zhou,Wei-Feng Qu,Zheng Tang,Han Wang,Chen-Yang Tao,Yuan Fang,Shuang-Jian Qiu,Jian Zhou,Jing-Feng Liu,Jia Fan,Ying-Hong Shi
DOI: https://doi.org/10.2147/cmar.s195964
2019-01-01
Cancer Management and Research
Abstract:Purpose: To develop and validate a decision aid to help make individualized estimates of tumor recurrence for patients with resected combined hepatocellular cholangiocarcinoma (CHC). Patients and methods: Risk factors of recurrence were identified in the derivation cohort of 208 patients who underwent liver resection between 1995 and 2014 at Zhongshan Hospital to develop a prediction score. The model was subsequently validated in an external cohort of 101 CHC patients using the C concordance statistic and net reclassification index (NRI). Results: On multivariate analysis, five independent predictors associated with tumor recurrence were identified, including sex, γ-glutamyl transferase, macrovascular invasion, hilar lymphoid metastasis and adjuvant transcatheter arterial chemoembolization. The prediction score was constructed using these 5 variables, with scores ranging from 0 to 5. A patient with a score of 0 had a predicted 1- and 5-year recurrence risk of 11.1% and 22.2%, respectively. In the validation cohort, the NRIs of prediction score vs American Joint Committee on Cancer 7th TNM staging system at 1-year and 5-year were 0.185 (95% CI, 0.090-0.279, P<0.001) and 0.425 (95% CI, 0.044-0.806, P=0.03), respectively. Conclusion: Our developed and validated prediction score might be a simple and reliable method in postoperative CHC patients and help clinicians identify candidates who may benefit from future adjuvant therapies.
What problem does this paper attempt to address?